PMN

3.1402.18%
LD

Larry Douglas Altstiel

Chief Medical Officer

Dr. Larry Douglas Altstiel is Acting CMO & Scientific Advisory Board Member of Serpin Pharma, LLC. Dr. Altstiel, M.D., Ph.D. serves as Chief Medical Officer at ProMIS Neurosciences, Inc since April 19, 2022. He joined Oncolyze, Inc. in 2019 as Chief Scientific Officer. He has served as Chief Scientific Officer of Oncolyze, Inc. since February 28, 2019. He serves as Chief Medical Officer at Pinteon Therapeutics, Inc since 2018. He has medical expertise in neurodegenerative diseases and experience in the pharmaceutical industry. He served as the Chief Medical Officer of vTv Therapeutics Inc. from December 02, 2015 to April 30, 2018 and as its Executive Vice President from January 17, 2016 to April 30, 2018. Dr. Altstiel served as the Chief Executive Officer of Provectra Biotherapeutics, an early-stage biotechnology company developing novel gene therapy for neurodegenerative diseases, from 2013 to 2015 and was its founder. He was responsible for all of Provectra's product development activities, while leading Provectra toward commercializing products based upon its proprietary gene therapy technologies. From 2007 to 2013, he served as Vice President of Neuroscience Clinical Development, Neuroscience Therapeutic Area Clinical Lead, at Pfizer Inc. His principal responsibilities were directing the PGRD Neuroscience Research Unit clinical research, which included governance, operational and budgetary responsibilities for: preclinical biology and first in human studies; supervising of transitional medical plans and related external alliances; supervising clinical teams conducting early phase clinical research from translational medicine through proof of concept and subsequent Phase 3 clinical trials. He was employed at Praecis Pharmaceuticals Inc. Dr. Altstiel's other positions included Senior Vice President, Head of Global Clinical Development, at Schwarz Biosciences, Inc., Vice President for Research Operations at Eisai Medical Research Inc. and Schering-Plough and Senior Clinical Research Physician and Group Leader for Neurodegenerative Diseases Clinical and Discovery Research for Alzheimer's Disease, Parkinson's Disease and Stroke at Eli Lilly and Company. Dr. Altstiel has gained extensive experience in psychiatry and neurology at Mount Sinai School of Medicine, Columbia Presbyterian Medical Center and Hospital and The Bronx Veteran's Administration Medical Center. He served as Senior Vice President, Clinical in March 2000. He was the Senior Clinical Research Physician and Group Leader for Neurodegenerative Diseases, focusing on Alzheimer's Disease, at Eli Lilly & Sons from January 1995 to March 2000. From July 1988 to December 1994, he was an attending physician at The Mount Sinai Medical Center. He served as a Member of Scientific Advisory Board at Neurotrope, Inc. since October 2013 and served as its Director since September 12, 2014 until February 11, 2016. During that time, he also served as the Director of the Division of Behavioral Neurology at the Bronx Veterans' Administration Medical Center and as a consulting physician at The Mount Sinai Alzheimer's Disease Research Center. Dr. Altstiel has published over 60 publications and abstracts on topics including neurodegenerative diseases such as Alzheimer's Disease and their related pharmacogenetics and potential treatments. Dr. Altstiel was a NIH Postdoctoral Fellow at The Biological Laboratories, Harvard University and trained in Internal Medicine at The Harlem Hospital and in Neurology at the Neurological Institute, Columbia. Dr. Altstiel earned his B.S. in Chemistry / Physics at the University of Illinois, his Ph.D. in Cell Biology, Virology and Physical Chemistry at The Rockefeller University and his M.D. at The University of Miami, Miller School of Medicine. He also completed a residency in neurology at the Neurological Institute of New York, Columbia University College of Physicians and Surgeons.

Positions